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ABSTRACT 
 Two major issues surround the U.S. healthcare system: waste and inaccessibility of 
prescription drug medication. This paper primarily examines the financial impact medication 
donation repositories have on individuals and the healthcare system overall. Healthcare facilities 
may act as repositories for donated medications to be dispensed to those otherwise unable to 
afford them. The specifics of each policy vary from state to state with some policies covering a 
wider array of acceptable donations than others. Although Kentucky enacted a policy in 2005, 
the state still lacks any operational programs. By analyzing the policies of multiple states, this 
paper elucidates the more comprehensive impact medication donation repositories have on the 
healthcare system. The Georgia program includes a wider array of medications while serving 
geographic areas and demographics similar to those of Kentucky. Alternatively, the longer 
existing programs in Iowa and Wyoming paint a more complete picture regarding the 
sustainability and effect of repository policies. While policies and programs exist separately 
pertaining to both medication donation and waste, like drug disposal and medication assistance 
programs, medication donation repository policies tackle multiple problems in the U.S. 
healthcare system. Instead of wasting unused medications that could benefit others, the 
medications can be donated for redistribution, which reduces environmental waste and the 
financial expenditures associated with healthcare.  
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INTRODUCTION 
 In Kentucky alone, medication costs total more than $5 billion annually, which is just a 
fraction of the more than $354 billion spent by the entire United States.1 Almost one-fifth of the 
billions of dollars spent on prescription medications comes directly out of patients’ pockets.2 
Additionally, the World Health Organization reports that only 50% of people in developed 
countries take their chronic disease medications as prescribed.3 In fact, 7.8% of adults in the U.S. 
admit to taking prescription medications incorrectly as a way to save money.4 The incidence of 
nonadherence to prescription medications varies based on insurance coverage. Incidence of 
nonadherence, as well as other cost-saving methods, increases from private insurance holders to 
Medicaid beneficiaries to the uninsured (Figure 1).5 Along with other reasons like prescribing 
too large of quantities and changes to therapies due to ineffectiveness or intolerability, 
nonadherence to medications results in increased waste and healthcare expenditures.6  
Figure 1: Percent of Adults Using Cost-Saving Strategies Due to Prescription Drug Costs, 2013  
Source: CDC/NCHS, National Health Interview Survey, 2013.  
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When considering waste generated by pharmaceuticals, there are two perspectives to 
consider: the physical pollution resulting from disposal and the inefficiency of prescribing 
resulting in unused medication. From a pollution standpoint, lack of knowledge regarding proper 
disposal practices may lead to environmental harm. Specifically, the U.S. regularly disposes of 
medications via the wastewater system, whether by toilet or sink.7 An analysis of fifty 
wastewater plants revealed at least 90% of samples contained various pharmaceutical products 
including multiple blood pressure medications and a mood stabilizing and antiepileptic 
medication.8 From sewage and septic systems, pharmaceutical compounds enter bodies of water 
and groundwater supplies. Not only do humans face harm from contaminated water supplies, but 
aquatic life is endangered by improper disposal practices. Similarly, medications disposed of via 
the trash also pose a threat to nearby aquifers.9 
 Due to water contamination, the Environmental Protection Agency (EPA) began looking 
at unused pharmaceutical disposal practices among healthcare facilities. To dispose of waste in a 
safer manner and reduce the overall amount of waste produced, the EPA created best 
management practice guidelines for healthcare facilities. The EPA first suggests various 
strategies to reduce waste: order smaller container sizes, utilize unit-dose packaging, and relocate 
medications that are close to expiring to an area of the facility where it will be used more 
frequently. Since it is illogical to expect a healthcare facility to operate with no waste, the EPA 
recognizes various ways for unused medications to be disposed of safely. From most to least 
preferred, the EPA endorses the following disposal methods: donation, reverse distribution, 
management as hazardous waste, solid waste incineration, and disposal in solid waste landfill 
after mixing with undesirable substance. However, the exact methods recommended for a 
specific product depend on the classification of the pharmaceutical product—hazardous, 
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nonhazardous, controlled substance, or chemotherapeutic agent.10 While the EPA focuses on safe 
disposal practices, it also addresses the volume of unused medication that could be redistributed 
to conserve waste.  
 Moving toward the wastefulness of the distribution process, U.S. healthcare facilities and 
households alike contribute to the problem. Inefficient dispensing of medications cannot be 
separated from increased healthcare expenditures as the former contributes to the latter. 
According to a prospective study of Medicare Part D beneficiaries in various skilled nursing 
facilities, almost 7% of dispensed medications are returned only partially used, which accounts 
for 3.5% of the cost of dispensing. Although the percentage of cost appears low, the total cost of 
unused medications represents $125 million in healthcare expenditures for a relatively small 
population sample when considering all healthcare consumers.11 Additionally, a survey of 1,228 
hospice nurses in Michigan reports that 44% of survey participants dispose of at least eleven 
doses of medication when a patient dies. Furthermore, the majority of these nurses feel it is either 
never acceptable, extremely unsafe, or unsafe to return medication to the hospice facility, further 
impeding a more sustainable system. Unfortunately, the survey did not inquire about the classes 
of medications that nurses typically discard.12  
When looking at unused medications in U.S. households, a survey of healthcare 
consumers in Southern California reveals that 67% of prescription medications go completely 
unused. This study projects a national average of 42% of all prescriptions going unused, creating 
enough dispensed medication to total 3.9 billion unnecessary prescriptions annually. From the 
study sample alone, unused medications account for between $59,264.20 and $152,014.89 of 
healthcare expenditures—the exact cost varying depending on the use of average retail price or 
average wholesale price. National estimates for unused medication costs spans anywhere 
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between $2.4 billion and $5.4 billion. Lastly, the most common classes of unused prescriptions 
include acute medications, like antibiotics and pain medications, and chronic medications for 
high blood pressure, diabetes, high cholesterol, and heart disease.13 
 Overall, the U.S. healthcare system operates inefficiently. Prescription medications 
represent a significant cost to healthcare facilities, healthcare consumers, and insurance 
companies. Consumers able to afford medications may be spending more than necessary, while 
those unable to afford medications must sacrifice their health and wellbeing. To increase access 
and affordability of care, many states enacted medication donation repository policies. 
Medication repositories are legitimate healthcare sites serving to accept properly stored and 
unadulterated medications for distribution among those unable to otherwise afford treatment. 
While many states have enacted policies to operate medication repositories, fewer states actually 
have operational facilities. The purpose of this project was to assess the impact medication 
donation repositories can have on providing access to much needed treatment for those in need. 
To call attention to the benefits of developing operational sites in Kentucky, this study examined 
the effects other states’ programs have had, specifically Georgia, Iowa, and Wyoming. Impacts 
of interest included the cost spared to both the healthcare system and those receiving the 
medication and the decrease in medication waste due to these programs.  
 
METHODS 
Policy Framework 
 To analyze medication donation repository policies, this study utilized the framework 
outlined in Eugene Bardach’s A Practical Guide for Policy Analysis: The Eightfold Path to More 
Effective Problem Solving. The eight steps for appropriate analysis include 1) defining the 
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problem, 2) assembling evidence, 3) constructing alternatives, 4) selecting criteria, 5) projecting 
outcomes, 6) confronting trade-offs, 7) deciding, and 8) telling your story. Steps one and two 
consisted of a literature search to examine the extent of the problem regarding the affordability 
of, access to, and waste produced by medications in the U.S. healthcare system. The first two 
steps are addressed in the introduction and “Scope of the Problem” portion of the results section. 
While assembling evidence, alternative solutions related to step three surfaced that either 
concurrently exist in the U.S. or have been postulated, which are covered in the “Policy 
Alternatives” portion of the interpretation. Criteria selected for step four largely pertained to the 
main problems discovered in step one: access, affordability and sustainability, and waste. The 
selected criteria assisted in step five’s projecting the outcomes of medication donation 
repositories and alternative solutions by looking at increased patient reach, money saved to both 
patients and the healthcare system, and reduced waste. Step five is addressed in both the results 
section for repository programs and “Policy Alternatives” in the interpretation section for other 
solutions. Trade-offs of step six were accounted for by creating a list of possible benefits and 
shortcomings of medication donation repository programs in regards to other solutions, which is 
found in the “Implications of Medication Donation Repositories” portion of the interpretation 
section. Finally, the discussion and conclusion represent steps seven and eight of Bardach’s 
framework, which further outlines the benefits and shortcomings of proposed solutions.  
 Due to the economic and political ties healthcare has in the U.S., this study must 
consider, to an extent, the effect that current and future political climates may have on the impact 
of repository policies and programs. To assess any political considerations, this study also 
utilizes Beaufort Longest’s framework outlined in Health Policymaking in the United States. The 
“Implications of Medication Donation Repositories” subsection of the interpretation section 
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delves into the political considerations of repository programs. While increasing efficiency and 
reducing waste may not be a source of bipartisan discord, the undecided changes to the 
healthcare system can drastically determine the utility of repository programs. Furthermore, the 
political considerations presented in this study are of a speculative nature because of the 
uncertain future of healthcare coverage.  
Literature Review Process 
 Information related to the scope of this study was found via the Google search engine and 
PubMed, which is primarily controlled by the United States National Library of Medicine 
database. The following words and phrases used in various combinations led to the facts and 
results outlined in this policy analysis: medication donation repository, Georgia, Iowa, Kentucky, 
Wyoming, USA, unused medication, hospital, nursing home, drug disposal, drug waste, cost of 
medication, healthcare expenditures, insurance coverage, uninsured, medication recycling, 
economic impact, and financial burden of medications. Inclusion criteria for useful data included 
being published within the past ten years from a reputable source, which was limited to scholarly 
articles and reports. Information was also included from national and international organizations, 
such as the Centers for Disease Control and Prevention, Centers for Medicare and Medicaid 
Services, Environmental Protection Agency, Kaiser Family Foundation, and World Health 
Organization. News articles were only utilized about Georgia’s policy, as it is too new to have 
other impact studies or data. Information was excluded from the study if it pertained to data 
outside of the U.S. 
Limitations 
 Despite a thorough analysis of medication donation repository policies, this study had 
several limitations. The most prevalent limitation lies within the lack of evaluative information 
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that exists pertaining to repository programs. While many states have operational programs, the 
data assessing the impact of the programs is not always present. Combining the available data 
with the discrepancies among policies, it was not possible to consistently report on the same 
measures for each policy. The selection of state policies to analyze was largely decided based on 
which states had existing data, presenting potential selection bias. Additionally, any financial and 
conservatory effects of repository programs are conveyed by the operative program itself, which 
presents an opportunity for reporting bias. Furthermore, as this study partially serves as a call-to-
action for Kentucky to implement operational programs, the effects of other states’ policies were 
analyzed and are used as surrogates to show the potential—not definitive—impact of programs 
in Kentucky.  
 
RESULTS 
Scope of the Problem 
 The ineffectiveness of the U.S. healthcare system cannot be boiled down to a single root 
cause. Due to differences in insurance coverage, patients face varying prices when paying for 
medications, if they can even afford their medications. In fact, individuals with multiple chronic 
conditions contribute over 80% of all prescription costs. Furthermore, of all individuals with 
multiple chronic conditions, 31.3% have private insurance, 25.5% have Medicaid, 87.4% have 
Medicare and Supplement, 80% have Medicare alone, 78% have Medicare and Medicaid, 58.6% 
have other government insurance, and 16% are uninsured.14 Nationally speaking, 8.8% of U.S. 
citizens—28.5 million people—are uninsured.15 Kentucky has a slightly lower uninsured rate of 
7%.16 In 2013, the average annual cost of prescription medications to individuals in the U.S. 
totaled $858, which could vary drastically depending on insurance coverage and may be 
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infeasible for many.17 Accordingly, a systematic review of various studies demonstrated that 
increased prescription drug insurance coverage simultaneously decreased the use of other 
healthcare resources while improving patient outcomes.18 
Additionally, approximately 60% of U.S. adults currently suffer from at least one chronic 
disease, and about 40% of U.S. adults carry the diagnoses of multiple chronic conditions.19 With 
the increase in chronic disease prevalence, the percentage of individuals taking prescription 
medication has subsequently increased. From 1999-2000 to 2011-2012, U.S. adults reporting the 
use of one prescription medication rose from 51% to 59%, and those reporting the use of five or 
more medications rose from 8% to 15%.20 Not only does insurance coverage impact the out-of-
pocket costs to patients, but costs also vary depending on the diagnosis and medications 
prescribed. As a leading driver of healthcare costs in the U.S., diabetes is one of the most 
common chronic conditions, affecting 29.1 million people.21,22 This single condition increases 
prescription expenditure by approximately $2,500 per person per year (Figure 2).23 
Figure 2: Annual Cost of Prescription Medications Based on Diabetes Diagnosis 
Source:  Ozieh et. al., 2015. 
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Along with the role insurance coverage, increased incidence of disease, and growing 
treatment options have in expenditures, waste also largely contributes to the inefficiency of 
healthcare. Estimates reveal that ten million prescriptions dispensed in the U.S. could be 
recycled, potentially representing $700 million in healthcare expenditure waste. Long-term 
healthcare facilities may waste as much as $2 billion of unexpired medications every year, and 
all sources of unexpired medication waste may total as much as $5 billion annually. Meanwhile, 
as many as 50 million individuals in the U.S. may be unable to afford needed medications.24 
Instead of wasting reusable medications that account for millions to billions in healthcare 
expenditures and leaving individuals undertreated and at-risk of further medical exacerbations, 
medication donation repositories help to bridge the gap of an unsustainable healthcare system. 
Policy Solution 
 Over the past 22 years, states have developed policies pertaining to medication donation 
repositories. Since the inception of repository legislative action in 1997, 38 states enacted 
repository policies, and 21 states began operational repository programs.25 Repository programs 
serve as a central hub for collecting donated, and previously dispensed, medications and 
redistributing it to qualified entities. If the program deems the donated medication unusable, then 
it is also responsible for properly disposing of it.26 The specifics of each statewide policy differ 
among states, with some states allowing a wider scope of permissible donations than others.  
Main points of diversion among policies include who can donate medications, who can accept 
medications, who is eligible to receive donations, and what medications can be donated.  
In regards to who can donate medications, some states require the donated medication 
come from other healthcare facilities, keeping the medications in a closed system to assure 
proper handling and storage techniques were used. Of these states, some policies narrow down 
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the types of healthcare facilities that can donate, such as only long-term care facilities. 
Alternatively, other states’ policies use language that permit any individual with unused 
medications to donate. Qualified accepting facilities vary drastically: pharmacies that originally 
dispensed the medication, any healthcare facility complying with legal stipulations, charitable 
clinics, any hospital facility, board-approved drop-off sites, physician offices, and many other 
restricted examples. Eligible recipients of donated medication typically consist of needy 
residents, whether they are uninsured, underinsured, indigent, meet the income requirement, an 
eligible healthcare professional, or meet eligibility outlined by other laws. Though, some policies 
extend eligible recipient coverage to any resident of the state. Donated materials may be limited 
to solely cancer drugs or may encompass any prescription drug, over-the-counter drugs, and/or 
medical supplies. Finally, states may place certain restrictions within their policies—the most 
common being an exclusion on donating controlled substances.27 
In Kentucky specifically, a policy pertaining to medication donation repositories was first 
enacted in 2005, and then repealed, reenacted, and renumbered in 2017.28 Per the original policy, 
the Cabinet for Health and Family Services (CHFS) was responsible for establishing and 
maintaining repository programs (See Appendix A).29 Since the CHFS oversees most human 
services and healthcare programs in Kentucky, like the Department of Medicaid and Department 
of Public Health, it was logical for repository programs to also fall under its regulation. 
However, the CHFS failed to promulgate administrative regulations, preventing the existence of 
operational programs. In 2017, the Board of Pharmacy assumed the role previously held by the 
CHFS.  Much of the language remained the same after the policy was reenacted (See Appendix 
B).30   
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Currently, Kentucky’s policy extends to include any legend drug, which according to 
KRS 217.015 is “a drug defined by the Federal Food, Drug and Cosmetic Act, as amended, and 
under which definition its label is required to bear the statement ‘Caution: Federal law prohibits 
dispensing without prescription.’"31 While the policy does not explicitly outline who can donate 
medications, KRS 315.454 states that the drug or supply be “in its original, unopened, sealed, 
and tamper-evident unit dose packaging or, if packaged in single-unit doses, the single-unit dose 
packaging is unopened” and that it is neither adulterated nor misbranded “as determined by a 
pharmacist employed by, or under contract with, the health facility or pharmacy.”32 Any health 
facility or pharmacy may act as a repository site, but involvement is strictly voluntary. Although 
a repository site may charge a set handling fee for dispensing the medication, the donated 
medication and supplies cannot be resold.33 Furthermore, the donated medications cannot be 
controlled substances, and recipients must have a valid prescription for the medication.34 Lastly, 
the repository facility determines its own eligibility criteria for recipients, which pertains to both 
individuals and healthcare facilities.35 
In the 14 years of Kentucky’s existing policy, no repository programs have been 
established. To analyze the benefit of repository policies, the effects of existing programs in 
Georgia, Iowa, and Wyoming were examined. As policies vary state-to-state, the major points of 
each policy are outlined before delving into the number of redistributed prescriptions, number of 
people assisted, dollars saved to individuals and/or the healthcare system, and the amount of 
reduced waste. However, by looking at different policies in different states, many confounding 
variables present themselves: the ability of a repository program to get in contact with surplus 
materials, prescribing habits of surrounding providers, number of healthcare facilities in the area, 
and the constraints of the policy itself among others. To account for these differences, the impact 
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of SIRUM—Supporting Initiatives to Redistribute Unused Medicine, an intermediary 
organization connecting donors to repository programs—is also outlined.  
Georgia 
 In 1997, Georgia created the first state law allowing medication reuse in long-term health 
facilities. Over the next 20 years, the policy went through several amendments until it became 
what it is today under O.C.G.A. § 31-8-301 et.seq., which gives operational oversight to the 
Georgia Department of Public Health.36 The most recent changes to the policy allow for over-
the-counter medications to be donated to the program in addition to prescription medications, as 
long as the donated medications are in unopened packaging.37 Due to the Department of Public 
Health’s authority, more explicit eligibility criteria is outlined in Chapter 511-5-12 of the Rules 
of the Department of Public Health (See Appendix C).38 Eligible donation repository sites consist 
of an array of healthcare facilities voluntarily participating in the program—pharmacies, clinics, 
hospitals, nursing homes and providers’ offices—and non-healthcare related sites, like 
wholesalers, distributors, and other entities participating in the program. Georgia permits 
donations from any individual regardless of association with a healthcare facility, government 
entity, wholesaler, or manufacturer. Finally, any person in need of medication may be an eligible 
recipient, but priority consideration is given to the indigent, uninsured, underinsured, and those 
enrolled in public assistance health benefits program.39 
 In 2018, as many as 17% of Georgia’s adults went without needed healthcare due to 
cost.40 Currently, only three facilities in Georgia serve as donation sites: Good Pill Pharmacy, 
Charitable Returns, and Crossroads Pharmacy.41 Of these entities, Good Pill Pharmacy is the first 
pharmacy to solely dispense surplus, donated medications. Most of the medications dispensed at 
Good Pill Pharmacy cost patients $6 for a 90-day supply and are shipped for free to patients. 
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Since the pharmacy is fully stocked with surplus medication, the inventory is sporadic, and a 
real-time list of available medication is updated online.42 In its first seven months of operation, 
Good Pill Pharmacy began providing medication to approximately 1,000 Georgians, with a 
monthly growth rate around 40%. Not only does Good Pill Pharmacy partner with SIRUM to 
acquire donations, but as of August 2018, local donations were garnered from around 20 nursing 
homes and five long-term care pharmacies. Well within its first year of operation, Good Pill 
Pharmacy estimates it dispensed more than $2 million in medications to those in need.43  
Iowa 
 Similar to Kentucky, Iowa began legislative consideration of medication donation 
repositories in 2005.44 Per Iowa Code § 135M, the Department of Public Health oversees the 
operations and regulates the specifics of repository programs via 641 IAC 109 (See Appendix 
D).45 The Prescription Drug Donation Repository Program in Iowa accepts all types of non-
controlled prescription medications, including cancer and anti-rejection medications and samples 
provided by manufacturers, and medical supplies. Any pharmacy or medical facility may act as a 
local repository: physician office, hospital, health clinic, and nursing facility. Additionally, any 
individual over the age of 18 may donate medications and supplies that a pharmacist inspects to 
ensure it is properly branded and unadulterated. Finally, recipients of donated materials must 
show proof of residence in Iowa and be either indigent, uninsured, or underinsured.46 
 Unlike Kentucky, a repository program began operating in Iowa in 2007, shortly after 
enacting the policy. The SafeNetRx program works with the Iowa Department of Public Health 
to provide medications and supplies to qualified individuals at the cost of a small handling fee if 
any fee at all.47 SafeNetRx currently places receptacles at nine different cancer centers 
throughout Iowa to collect donated cancer medications. Furthermore, the program works with the 
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Iowa Safety Net Pharmacy, which ships affordable medications to individuals in need for free. 
Patients utilizing the Safety Net Pharmacy typically pay $10 for a 30-day supply of their first 
prescription and $3 for each subsequent prescription.48 
 After eight years of operation, SafeNetRx conducted a comprehensive performance 
report in 2016. In addition to the nine cancer centers who partner with the program to attain 
donations, more than 250 other healthcare centers act as repository sites for SafeNetRx. To 
justify the sustainability of the Iowa Drug Donation Repository, the program reports a return on 
investment of $7 in free medications and supplies for every $1 invested. From 2007 to 2016, 
SafeNetRx provided more than 71,000 Iowans with needed medications and medical supplies. 
Donations over the first nine years of operation total more than 9 million units in free medication 
and supplies to those in need, which corresponds to over $17 million in cost-savings (Figure 3).49 
Whether patients meet the federal poverty level, are uninsured, or underinsured, SafeNetRx 
provides patient testimonials and financial data for each scenario. One beneficiary of Iowa’s 
repository program has Medicare coverage and receives low-income subsidies, but none of the 
three medications she takes qualifies for any insurance coverage. Without insurance 
reimbursement, this patient faces a monthly cost over $650 for her medications. Instead, the 
repository program provides the patient with these medications for a fraction of the price. 
Another beneficiary lost Medicaid coverage after receiving a $1 raise and two consecutive $250 
bonuses. While she could reapply for Medicaid in three months, her raise and bonuses would be 
insufficient to cover her out-of-pocket prescription costs in the meantime. During her uninsured 
period, the repository program provided the patient with her prescriptions and saved her over 
$1,700.50 
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Figure 3: Impact of SafeNetRx, 2008-2016 
 
Source: SafeNetRx Performance Update, 2016. 
Wyoming 
 Wyoming’s drug donation repository history is akin to Iowa’s: legislative action 
occurring in 2005 that led to operational programs within the next few years.51 The policy, WY 
Stat § 35-7-1601 et.seq., gives supervisory authority to the Wyoming Department of Health, 
which further describes the operational constraints of the state’s repository programs (See 
Appendix E).52 Any prescription medication can be donated to the Wyoming Medication 
Donation Program (WMDP); however, all controlled substance medications are only to be 
collected for disposal, not redistribution. Healthcare facilities of all kinds may accept donations, 
ranging from hospitals to assisted living facilities. To maximize inventory and care to those in 
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need, any resident of Wyoming may donate medications regardless of their healthcare 
affiliations. Medications obtained at take-back events are also eligible for donation.53 While the 
enacted policy does not explicitly outline eligible recipients of donated medications, the 
Wyoming Department of Health website states the program serves low-income, uninsured, and 
underinsured individuals.54  
 According to the most recent publishing, Wyoming offers 31 locations across the state 
where patients can donate their unused medications.55 The WMDP has filled more than 150,000 
prescriptions since its inception in 2007. These 150,000 prescriptions account for more than 
$12.5 million, which, when divided evenly, translates to slightly over $83 per prescription. In 
2016 alone, over $2.4 million worth of prescription medications were donated and redistributed 
to individuals in need.56 Not only does the WMDP focus on the importance of donating unused 
medications, but it recognizes the environmental significance of proper disposal of unused 
medication. The 31 drug donation receptacles across the state also serve as disposal boxes for 
unacceptable donations, along with 34 other sites designated solely as disposal locations.57 From 
mid-2008, the WMDP redistributed more than 88,000 pounds of donated medications and 
supplies that may have been improperly disposed of otherwise. Almost 20,000 pounds of 
unacceptable donated medications have been safely incinerated by the WMDP since 2009, 
reducing environmental waste and the potential for accidental poisonings and drug abuse.58 
SIRUM 
 Founded in California in 2011, SIRUM works to connect healthcare facilities with 
surplus medications to healthcare facilities in need of donated medications for patients unable to 
afford them. Operational sites associated with SIRUM exist in California, Colorado, Georgia, 
Iowa, and Ohio.59 Additionally, SIRUM partners with the WMDP and accepts donations from 
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varying types of healthcare facilities, manufacturers, and wholesalers in other states.60 In its eight 
years of operation, more than $17 million in medications have been donated and dispensed to 
individuals in need, corresponding to a retail value greater than $51 million and totaling more 
than 870,000 prescriptions.61 Moreover, 150,000 patients unable to afford prescriptions benefit 
from SIRUM’s efforts. These donations prevent more than 240,000 pounds of waste that 
manufacturing new medications would create.62 Figure 4 summarizes the main points of these 
states’ policies.  
Figure 4: Summary Table of States’ Repository Policies 
 
INTERPRETATION 
Policy Alternatives 
 With states considering repository programs for well over the past ten years, the 
inefficiencies plaguing the U.S. pharmaceutical healthcare industry are not newly realized. 
Therefore, several other policies function to correct the imbalances of the healthcare system. One 
State: Who Can Accept: Who Can Donate: Who Is Eligible: What Can Be Donated:
Georgia
Various healthcare facilities, 
entities involved in the 
distribution process, and 
facilities choosing to 
participate in repository 
programs
Any individual or entity in 
lawful possession of donated 
materials 
Primarily indigent individuals 
and then others in need of 
medication given that inventory 
is sufficient  
Prescription and over-the-
counter medications, excluding 
controlled substances
Iowa
Medical facilities (clinics, 
physician offices, hospitals) 
and pharmacies
Individuals 18 years of age 
and older in legal possession 
of medications
Indigent individuals Prescription drugs, excluding controlled substances
Kentucky Health facilities and pharmacies Not explicitly stated
Specific eligibility criteria to be 
determined, prioritizing the 
uninsured and indigent
Legend drugsҰ and supplies 
needed to administer them, 
excluding controlled 
substances
Wyoming
Healthcare facilities, 
pharmacies, take back events, 
and donation sites overseen by 
the WDH
Any individual or entity Residents of Wyoming with limited resources Prescription drugs
* Indigent refers to those who are uninsured, underinsured, enrolled in a public assistance health benefits program, or meet income eligibility 
Ұ Legend drugs are defined by the FDA as drugs that require a label stating "Caution:  Federal law prohibits dispensing without prescription" 
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of the most widespread and utilized programs is authorized by 21 CFR 1317, which deals with 
the disposal of unwanted, and perhaps expired, medications. Individuals needing to discard 
prescriptions may seek out various options: take-back events, mail-back programs, and collection 
receptacles placed at participating locations. Facilities authorized to act as collection sites 
include community pharmacies, hospitals and clinics with on-site pharmacies, manufacturers, 
distributors, reverse distributors, and narcotic treatment programs. 63  
Unlike repository programs, drugs brought to take-back events, mailed to registered 
locations, or left at receptacles are destroyed, not reused. Annually, the Drug Enforcement 
Administration (DEA) assigns at least one calendar day to be the National Prescription Drug 
Take-Back Day. These events also provide an opportunity to educate individuals about potential 
medication abuse and associated harms.64 From 2010 to October 2018, the DEA and its partners 
safely disposed of almost ten million pounds of prescription medications at take-back events.65 In 
Kentucky, more than 135,000 pounds of medication have been collected at take-back events 
alone since 2011. Apart from take-back events, Kentucky law enforcement and local government 
agencies offer 198 collection receptacles in 116 counties across the state.66 Forty-one of these 
sites are associated with Operation UNITE, a non-profit organization in Southeastern Kentucky 
working to mitigate substance abuse.67 Over the past seven years, Operation UNITE drop boxes 
have sequestered over 27,000 pounds of medications—3,700 pounds of which were obtained 
from the October 2018 Take-Back Day alone.68 While this solution addresses issues of 
environmental contamination, waste, and potential misuse of medications, it fails to address the 
barriers blocking access to pharmaceutical care. 
 Alternatively, medication assistance programs alleviate the financial barriers that impede 
pharmaceutical care. Many medication assistance programs are offered by pharmaceutical 
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companies, and enrollment in these programs allows patients to receive needed medications at no 
or a very low cost. Although each program is unique, most require enrollees to provide in-depth 
medical and financial information, like disease states, medications, income statements, and any 
health insurance information. Furthermore, healthcare professionals typically have to attest for 
each patient trying to enroll because the medications will be sent to the professional for 
distribution to the patient.69 A study out of Washington looked at the utilization rate of hospitals 
and emergency departments before and after patients enrolled in the Spokane Prescription 
Assistance Network program. Enrollment in this program correlated with a 51% decrease in 
emergency department and hospital utilization rate. Patient prescription coordinators connect 
patients in need with prescriptions they can afford, which further enables patients and the 
healthcare system to save money on unnecessary hospital and emergency department visits.70 To 
quantify the direct savings medication assistance programs produce, a retrospective study at two 
community health centers found the average prescription cost to be $0.11, saving patients an 
average of $617.36.71 Once again, these programs only focus on one part of the problem by 
correcting the inaccessibility of medication without tackling the issue of waste. 
 Simultaneously, the ability of pharmaceutical companies to provide medication at a very 
reduced or free price brings another solution into play: more stringent regulations on 
pharmaceutical industry pricing and spending. Companies spend ten years to get one drug on the 
market, possibly making the cost of medications seem more reasonable. Direct expenses, like 
salaries, clinical trials, labs, and manufacturing costs, make up $1.4 billion. Capital costs, or the 
money companies estimate they forego by pursuing an unproven drug, account for $1.2 billion. 
Regardless of the breakdown, the research and development cost behind one new medication is 
approximately $2.6 billion. Meanwhile, pharmaceutical companies annually spend $24 billion in 
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marketing costs to healthcare professionals alone.72 An additional $6.1 billion was allocated to 
direct-to-consumer advertising in 2017 (Figure 5).73  
Figure 5: Direct-to-Consumer Spending of the U.S. Pharmaceutical Industry, 2012-2017 
Source: Statista, 2018.  
Significant spending by the pharmaceutical industry is also tied up in politics. As a 
whole, the pharmaceutical industry donated over $41 million to political campaigns in 2018. The 
majority of donations usually go to Republicans, like in 2018, when 52% of contributions were 
to Republicans, and Democrats received the remaining 48%.74 Annual lobbying expenses have 
grown significantly over the past 20 years, from $69.1 million in 1998 to $280.31 million in 
2018 (Figure 6).75 Ultimately, however, regulating drug prices only creates more affordable 
products, and price controls would likely remain insufficient for some. Regulating 
pharmaceutical pricing is one piece of the puzzle in correcting the inefficiencies of the U.S. 
healthcare system, but political affiliations pose a monumental barrier in implementing these 
regulations.  
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Figure 6: Annual Lobbying Expenses for Pharmaceutical and Health Products Industry 
Source: Center for Responsive Politics, 2018.  
Implications of Medication Donation Repositories 
 Political climates also play a role in the efficacy and impact of medication donation 
repositories. The underlying principles of repository programs—to reduce waste in the healthcare 
system while increasing access to treatment—likely reap bipartisan approval, given that they are 
cost-effective. Therefore, the existence of repository programs is not largely threatened by 
changes in controlling political parties. Conversely, the utility of repository programs may 
drastically change depending on government actions pertaining to healthcare policy changes and 
spending. President Trump’s 2020 budget proposal suggests increasing healthcare spending for 
veterans, enforcing price transparency for prescription drug prices, decreasing funding for the 
Department of Health and Human Services, and revamping Medicare and Medicaid, which 
would result in budget cuts.76,77 However, a budget proposal is indefinite, and the true effects of 
funding changes cannot be extrapolated accurately. Meanwhile, in late February 2019, House 
Democrats proposed a Medicare for All bill, expanding the demographic covered and replacing 
Medicaid. This bill recreates the U.S. healthcare system as a federally-funded entity while 
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providing insurance to all citizens.78 Overall, politics play a significant role in the utility of 
repository programs.  
 Like any intervention, the benefits must be weighed against the costs. To continue 
operating repository programs, they must prove to be cost-effective, especially to comply with 
reducing healthcare expenditure waste. Most of the programs discussed in this paper have 
pharmacies that strictly dispense donated medications. Operating pharmacies incur many 
different expenses: the cost of the physical facility and utilities; salaries of employees; 
equipment, like computers, software, refrigerators, shelving, printers, and paper; materials 
needed for dispensing medications, like vials, bottles, and blister packs. If these pharmacies only 
distribute donated medication and only charge a handling fee in some cases, then the revenue 
generated to sustain itself is much lower than that of a traditional community pharmacy.  
The Texas Department of State Health Services issued a request for information 
regarding drug donation programs. A nonprofit organization associated with drug donation 
programs responded with funding estimates broken down by year. For the first year, the program 
would likely require $750,000, which would then decrease to $500,000, $300,000, and $150,000 
for each additional year of operation. By year five, the program should be self-sustaining from its 
own revenues. Furthermore, significant reductions in expenses are possible if programs exist as 
multistate centralized repositories. Both the size of the repository facility and the number of 
employees needed depend on the potential population served. While the size of the facility may 
vary drastically from a few hundred square feet to several thousand square feet, three is the 
lowest number of employees necessary for operations: a pharmacist, technician, and staff 
member to manage partnerships. Other suggestions for creating revenue include charging 
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recipients a handling or administrative fee and charging donors a fee that they likely incur at a 
higher rate for disposing of unused medications.79  
 Alternatively, if the repository program operates under an existing and traditional 
pharmacy, costs may be sustained due to an increased workload. Technicians must spend more 
time sorting, preparing, and dispensing medications, and pharmacists must take time to confirm 
that the medication is safe to be redistributed. Also, if donated medications prove unacceptable 
for distribution, the accepting facility must pay the price for disposing of the medications as no 
reimbursement codes exist for donated medications. While most programs likely work diligently 
to connect patients to needed medications, the inconsistency in the inventory of repository 
programs increases the likelihood of patients going without medications and experiencing 
incontinuity of care. At the same time it should be noted that repository programs were never 
designed to be long-term solutions for patients.  
 Additional concerns surround the legitimacy of donated medications being unadulterated. 
Restricting donations from healthcare sources alone better ensures the appropriate handling and 
storage of drugs, but definitive practices cannot be guaranteed upon disbursement. Although 
policies prohibit legal action against parties affiliated with repository programs in regard to 
harm, healthcare professionals may remain hesitant to risk their license by recommending or 
assisting in repository programs. Lastly, awareness of repository programs poses a barrier in 
their potential impact. To connect patients in need with medications, various entities and 
individuals—healthcare professionals, homeless shelters, insurance companies, government 
offices, health departments, and more—must be aware of existing programs and advocate for 
their use.  
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DISCUSSION 
 Overall, inefficiencies plaguing the U.S. healthcare system are multifaceted and require 
multiple interventions for complete resolution. Excessive physical and financial waste and 
inaccessibility of needed medications comprise two major inefficiencies of the system. The 
purpose of this study was to evaluate the impact of one solution, medication donation repository 
programs. Through the analysis of multiple operating repository programs, data revealed these 
programs prevent hundreds of thousands of pounds in pharmaceutical waste, dispense millions of 
dollars in medication that would otherwise go unused, provide medications to tens to hundreds of 
thousands of individuals in need, and save patients hundreds to thousands of dollars in 
prescription medication costs annually. However, many expenses follow the implementation of a 
repository program, perhaps negating its cost-saving effects. Unfortunately, the true financial 
impact of repository programs cannot be assessed as the down-stream effects of improved access 
to medication and continuity of care are unable to be definitively deduced. 
 Other solutions vary both in their impacts and feasibilities. Drug disposal programs and 
DEA take-back events greatly reduce the physical waste and environmental pollution produced 
by consumer disposal practices but fail to address financial waste and inaccessibility of care. 
Moreover, these interventions are well-established and practical in their implementation. 
Conversely, medication assistance programs offer affordable care options to those in need 
without tackling the issue of waste, and the lack of clarity and consistency among programs 
inhibits their utility. Least feasible of solutions is the restructuring of the U.S. healthcare system 
by political intervention. Although this solution would largely tackle the issue of inaccessibility, 
it could potentially touch on the aspect of waste depending on the depth of the restructuring and 
restrictions placed on the pharmaceutical industry.  
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CONCLUSION 
Ultimately, medication donation repository programs provide feasible solutions to waste 
and lack of access to care—two major public health concerns. Additionally, barriers preventing 
implementation in Kentucky were eliminated with the 2017 reenactment giving regulatory 
authority to the Board of Pharmacy, making repository programs even more feasible solutions. 
Still, repository programs represent a downstream intervention. In other words, they treat the 
symptoms of the problem without correcting the problem. Considering the time, money, and 
hesitancies associated with implementing and using repository programs, more evaluations and 
data must be compiled regarding the potential impact of the programs. In the meantime, the 
efforts of repository programs are insufficient and, therefore, need to be paired with other 
interventions until a permanent solution is reached. A major barrier to alleviating these issues is a 
lack of knowledge about available resources. Healthcare and public health professionals must act 
as conduits of information to connect patients and entities to resources, whether for the purposes 
of donating excess medication or receiving needed treatment. As a country, the U.S. must do 
more to protect our land, natural resources, and the health of our people.  
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APPENDIX A:  Kentucky Drug Repository Policy, 2005 
194A.450 Definitions for KRS 194A.450 to 194A.458.  
For the purposes of KRS 194A.450 to 194A.458: 
1) "Controlled substance" has the same meaning as in KRS 218A.010;  
2) "Dispense" has the same meaning as in KRS 217.015;  
3) "Health care provider" has the same meaning as in KRS 304.17A-005;  
4) "Health facility" has the same meaning as in KRS 216B.015;  
5) "Legend drug" has the same meaning as in KRS 217.015; 
6) "Pharmacist" has the same meaning as in KRS 315.010; and  
7) "Prescription drug" has the same meaning as in KRS 315.010.  
 
194A.452 Legend Drug Repository Program to be established -- Purpose -- Permitted donations -- 
Voluntary participation -- Handling fee -- Distribution.  
 
(1) The Cabinet for Health and Family Services shall establish and maintain a legend drug repository 
program to support the donation of a legend drug or supplies needed to administer a legend drug for use 
by an individual who meets the eligibility criteria specified by an administrative regulation promulgated 
by the cabinet. The repository program shall not accept any controlled substance.  
 
(2) Donations may be made on the premises of a health facility or pharmacy that elects to participate in 
the program and meets requirements specified by the cabinet by an administrative regulation promulgated 
by the cabinet.  
 
(3) The health facility may charge a handling fee to an individual who received a legend drug or supplies 
under the program established under this section, except that the fee shall not exceed the amount 
established by an administrative regulation promulgated by the cabinet.  
 
(4) A health facility or pharmacy that receives a donated legend drug under this section may distribute the 
legend drug or supplies to another eligible health facility or pharmacy for use under the program created 
under this section.  
 
(5) Nothing in this section or KRS 194A.454 shall require a health facility, pharmacy, pharmacist, or 
practitioner to participate in the program established in this section. 
 
194A.454 Requirements for accepting and dispensing legend drug or administration supplies.  
 
(1) A legend drug or supplies used to administer a legend drug may be accepted and dispensed under the 
program established in KRS 194A.452 only if the following requirements are met:  
 
(a) The legend drug or supplies needed to administer the legend drug is in its original,  
unopened, sealed, and tamper-evident unit dose packaging or, if packaged in single-unit  
doses, the single-unit dose packaging is unopened;  
 
(b) The legend drug is not classified as a controlled substance;  
 
(c) The legend drug or supplies needed to administer a legend drug is not adulterated or 
misbranded, as determined by a pharmacist employed by, or under contract with, the health 
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facility or pharmacy, who shall inspect the drug or supplies needed to administer a legend drug 
before the drug or supplies are dispensed; and 
 
(d) The legend drug or supplies needed to administer a legend drug are prescribed by a physician, 
advanced practice registered nurse, or physician assistant and dispensed by a pharmacist. 
 
(2) No legend drug or supplies needed to administer a legend drug that are donated for use under this 
section may be resold. 
 
194A.456 Immunity from civil liability -- Exceptions.  
 
(1) Unless the manufacturer of a legend drug or supply needed to administer a legend drug exercises bad 
faith or fails to exercise ordinary care, the manufacturer of a legend drug or supply shall not be subject to 
criminal or civil liability for injury, death, or loss to a person or property for matters related to the 
donation, acceptance, or dispensing of the drug or supply under the legend drug repository created under 
KRS 194A.452, including liability for failure to transfer or communicate product or consumer 
information or the expiration date of the donated drug or supply.  
 
(2) Health facilities, pharmacies, and health care providers shall be immune from civil liability for injury 
to or the death of an individual to whom a legend drug or supply is dispensed and shall not be subject to 
disciplinary action for unprofessional conduct for their acts or omissions related to donating, accepting, 
distributing, or dispensing a legend drug or supply under KRS 194A.450 to 194A.458, unless the act or 
omission involves reckless, wanton, or intentional misconduct or the act or omission results from failure 
to exercise ordinary care. 
 
194A.458 Required administrative regulations.  
 
The Cabinet for Health and Family Services shall promulgate administrative regulations to establish:  
 
(1) The requirements for health facilities and pharmacies to accept and dispense donated legend drugs or 
supplies needed to administer legend drugs under KRS 194A.452 and 194A.454, including all of the 
following:  
 
(a) Eligibility criteria for health facilities;  
 
(b) Standards and procedures for accepting, safely storing, and dispensing donated legend drugs 
or supplies needed to administer legend drugs;  
 
(c) Standards and procedures for inspecting donated legend drugs or supplies needed to 
administer legend drugs to determine if these are in their original, unopened, sealed, and tamper-
evident unit dose packaging or, if packaged in single-unit doses, the single-unit dose packaging is 
unopened; and  
 
(d) Standards and procedures for inspecting donated legend drugs or supplies needed to 
administer legend drugs to determine that these are not adulterated or misbranded;  
 
(2) Eligibility criteria for individuals to receive donated legend drugs or supplies needed to administer 
legend drugs dispensed under KRS 194A.452 and 194A.454;  
 
(3) Standards for prioritizing the dispensation to individuals who are uninsured or indigent, or to others if 
an uninsured or indigent individual is unavailable; 
43 
 
(4) A means by which an individual who is eligible to receive a donated legend drug or supplies needed to 
administer a legend drug may indicate that eligibility;  
 
(5) Necessary forms for administration of the legend drug repository program;  
 
(6) The maximum handling fee that a health facility may charge for accepting, distributing, or dispensing 
donated legend drugs or supplies needed to administer legend drugs;  
 
(7) A list of legend drugs and supplies needed to administer legend drugs that the legend drug repository 
program may accept for dispensing; and  
 
(8) A list of legend drugs and supplies needed to administer legend drugs that the legend drug repository 
program shall not accept for dispensing, including the reason why the legend drug or supply is ineligible 
for donation. 
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APPENDIX B: Kentucky Drug Repository Policy, 2017 
315.450 Definitions for KRS 315.450 to 315.460.  
 
For the purposes of KRS 315.450 to 315.460:  
 
1) "Controlled substance" has the same meaning as in KRS 218A.010;  
2) "Dispense" has the same meaning as in KRS 217.015;  
3) "Health care provider" has the same meaning as in KRS 304.17A-005;  
4) "Health facility" has the same meaning as in KRS 216B.015;  
5) "Legend drug" has the same meaning as in KRS 217.015;  
6) "Pharmacist" has the same meaning as in KRS 315.010; and  
7) "Prescription drug" has the same meaning as in KRS 315.010. 
 
315.452 Legend Drug Repository Program to be established -- Purpose -- Permitted donations - - 
Voluntary participation -- Handling fee -- Distribution.  
 
(1) The board shall establish and maintain a legend drug repository program to support the donation of a 
legend drug or supplies needed to administer a legend drug for use by an individual who meets the 
eligibility criteria specified by an administrative regulation promulgated by the board. The repository 
program shall not accept any controlled substance.  
 
(2) Donations may be made on the premises of a health facility or pharmacy that elects to participate in 
the program and meets requirements specified by the board by an administrative regulation promulgated 
by the board.  
 
(3) The health facility may charge a handling fee to an individual who received a legend drug or supplies 
under the program established under this section, except that the fee shall not exceed the amount 
established by an administrative regulation promulgated by the board.  
 
(4) A health facility or pharmacy that receives a donated legend drug under this section may distribute the 
legend drug or supplies to another eligible health facility or pharmacy for use under the program created 
under this section.  
 
(5) Nothing in this section or KRS 315.454 shall require a health facility, pharmacy, pharmacist, or 
practitioner to participate in the program established in this section.  
 
315.454 Requirements for accepting and dispensing legend drug or administration supplies.  
 
(1) A legend drug or supplies used to administer a legend drug may be accepted and dispensed under the 
program established in KRS 315.452 only if the following requirements are met:  
 
(a) The legend drug or supplies needed to administer the legend drug is in its original, unopened, 
sealed, and tamper-evident unit dose packaging or, if packaged in single-unit doses, the single-
unit dose packaging is unopened;  
 
(b) The legend drug is not classified as a controlled substance;  
 
(c) The legend drug or supplies needed to administer a legend drug is not adulterated or 
misbranded, as determined by a pharmacist employed by, or under contract with, the health 
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facility or pharmacy, who shall inspect the drug or supplies needed to administer a legend drug 
before the drug or supplies are dispensed; and  
 
(d) The legend drug or supplies needed to administer a legend drug are prescribed by a physician, 
advanced practice registered nurse, or physician assistant and dispensed by a pharmacist.  
 
(2) No legend drug or supplies needed to administer a legend drug that are donated for use under this 
section may be resold.  
 
315.456 Immunity from civil liability -- Exceptions. 
 
(1) Unless the manufacturer of a legend drug or supply needed to administer a legend drug exercises bad 
faith or fails to exercise ordinary care, the manufacturer of a legend drug or supply shall not be subject to 
criminal or civil liability for injury, death, or loss to a person or property for matters related to the 
donation, acceptance, or dispensing of the drug or supply under the legend drug repository created under 
KRS 315.452, including liability for failure to transfer or communicate product or consumer information 
or the expiration date of the donated drug or supply. 
 
(2) Health facilities, pharmacies, and health care providers shall be immune from civil liability for injury 
to or the death of an individual to whom a legend drug or supply is dispensed and shall not be subject to 
disciplinary action for unprofessional conduct for their acts or omissions related to donating, accepting, 
distributing, or dispensing a legend drug or supply under KRS 315.450 to 315.460, unless the act or 
omission involves reckless, wanton, or intentional misconduct or the act or omission results from failure 
to exercise ordinary care. 
 
315.458 Required administrative regulations. 
 
The board shall promulgate administrative regulations to establish: 
(1) The requirements for health facilities and pharmacies to accept and dispense donated legend drugs or 
supplies needed to administer legend drugs under KRS 315.452 and 315.454, including all of the 
following: 
 
(a) Eligibility criteria for health facilities; 
 
(b) Standards and procedures for accepting, safely storing, and dispensing donated legend drugs 
or supplies needed to administer legend drugs; 
 
(c) Standards and procedures for inspecting donated legend drugs or supplies needed to 
administer legend drugs to determine if these are in their original, unopened, sealed, and tamper-
evident unit dose packaging or, if packaged in single-unit doses, the singleunit dose packaging is 
unopened; and  
 
(c) Standards and procedures for inspecting donated legend drugs or supplies needed to 
administer legend drugs to determine that these are not adulterated or misbranded; 
 
(2) Eligibility criteria for individuals to receive donated legend drugs or supplies needed to administer 
legend drugs dispensed under KRS 315.452 and 315.454; 
 
(3) Standards for prioritizing the dispensation to individuals who are uninsured or indigent, or to others if 
an uninsured or indigent individual is unavailable; 
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(4) A means by which an individual who is eligible to receive a donated legend drug or supplies needed to 
administer a legend drug may indicate that eligibility; 
 
(5) Necessary forms for administration of the legend drug repository program; 
 
(6) The maximum handling fee that a health facility may charge for accepting, distributing, or dispensing 
donated legend drugs or supplies needed to administer legend drugs; 
 
(7) A list of legend drugs and supplies needed to administer legend drugs that the legend drug repository 
program may accept for dispensing; and 
 
(8) A list of legend drugs and supplies needed to administer legend drugs that the legend drug repository 
program shall not accept for dispensing, including the reason why the legend drug or supply is ineligible 
for donation. 
 
315.460 Restriction on acceptance or distribution of certain drugs. 
 
Drugs that shall only be dispensed to a patient registered with the drug's manufacturer in accordance with 
federal Food and Drug Administration requirements shall not be accepted or distributed under the 
provisions of the program. 
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APPENDIX C: Georgia Donated Drug Repository Policy 
Subject 511-5-12 DONATED DRUG REPOSITORY PROGRAM 
 
Rule 511-5-12-.01 Definitions 
As used in this Chapter, the term: 
 
1) "Controlled substance" means a drug, substance, or immediate precursor in Schedules I through V of 
Code Sections 16-13-25 through 16-13-29 and Schedules I through V of 21 CFR Part 1308. 
2) "Donor" shall mean any person, including an individual member of the public, or any entity legally 
authorized to possess drugs with a license or permit in good standing in the state in which it is 
located, including but not limited to a wholesaler or distributor, third party logistic providers, 
pharmacy, dispenser, clinic, surgical or health center, detention and rehabilitation centers, laboratory, 
medical or pharmacy school, prescriber or other health care professional, or healthcare facility. Donor 
shall also mean government agencies and entities that are federally authorized to possess drugs 
including but not limited to drug manufacturers, repackagers, relabelers, outsourcing facilities, 
Veteran Affairs hospitals, and prisons. 
3) "Drugs" means both prescription and non-prescription ("over-the-counter") drugs. 
4) "Eligible patient" means an indigent person; provided, however, that if the recipient's supply of 
donated drugs exceed the need for donated drugs by indigent patients, then any other person in need 
of a particular drug can be an eligible patient. 
5) "Eligible recipient" means a pharmacy, wholesaler, reverse distributor, hospital, federally qualified 
health center, nonprofit clinic, healthcare facility, an entity participating in a drug donation or 
repository program pursuant to another state's law, or private office of a healthcare professional 
which has been authorized by the Office of Pharmacy of the Department of Public Health as provided 
in DPH Rule 511-5-12-.04. 
6) "Healthcare facility" means a facility licensed by the Georgia Department of Community Health in 
accordance with Title 31, Chapter 7 as a: 
a. Nursing home; 
b. Personal care home; 
c. Assisted living community; 
d. Residential care facility for the elderly; 
e. Hospice; 
f. Hospital; 
g. Home health agency; or 
h. A similar entity licensed in the state in which it is located. 
7) "Health care professional" means a person who is licensed by the State of Georgia to practice as 
a: 
a. Physician; 
b. Registered nurse or licensed practical nurse; 
c. Physician assistant; 
d. Dentist or dental hygienist; 
e. Optometrist; or 
f. Pharmacist 
8) "Indigent patient" means a patient whose income is at or below the income eligibility 
requirements of the Georgia Medicaid program, or who is uninsured, underinsured, or enrolled in 
a public assistance health benefits program. 
9) "Program" means the donated drug repository program established by this Department pursuant 
to Code Section 31-8-301. 
10) "Transaction date" means the date on which ownership of the drugs is transferred between two 
participants of the program as established by contract or other arrangement. If no such contract or 
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arrangement exists, the transaction date shall be the date the drug was accepted into inventory by 
the recipient. 
 
Rule 511-5-12-.02 Authority and waivers 
1) A donor or eligible recipient may request a waiver or variance from the Department with regard 
to any regulation related to this program in accordance with DPH Rule 511-1-1-.05. 
Notwithstanding DPH Rule 511-1-1-.05(2)(a), a donor or eligible recipient may request a waiver 
or variance from any provision of Title 31, Chapter 8, Article 10, upon a showing that such action 
would be in the interest of public health and safety. 
2) Pursuant to Code Section 31-8-304, this Department and its rules have sole regulatory authority 
over the program. Notwithstanding any other administrative regulation, including but not limited 
to Ga. R. &Regs. 
a. 480-10-.17, 480-24-.05 (2)(b), and 480-24-.06, a person or entity may dispose of an 
eligible drug by donating it to an eligible recipient in accordance with the rules of this 
program. 
b. 480-10-.21 and 480-16-.08, an eligible recipient including but not limited to a pharmacy 
may receive drugs from a donor as defined in 511-5-12-.01 (2) in accordance with the 
rules of this program. 
c. 480-7-.03 (7)(e)(1), an eligible recipient may accept donated drugs that are in tamper-
evident packaging in accordance with DPH Rule 511-5-12-.03(1)(b), including but not 
limited to drugs that have a tamper-evident seal on either their immediate, outer, 
secondary, or shipping container. 
d. 480-7.02(1)(d), an eligible recipient, including but not limited to a pharmacy, may 
receive, accept, replenish, repackage, and store donated drug samples in accordance with 
the rules of this program. 
 
Rule 511-5-12-.03 Eligible drugs 
1) Drugs shall only be dispensed pursuant to the program if: 
a. For prescription drugs, they do not expire before the completion of the medication by the 
eligible patient based on the prescribing health care professional's directions for use and, 
for over-the-counter drugs, they do not expire before use by the eligible patient based on 
the directions for use on the manufacturer's label; and 
b. The drugs were donated in unopened tamper-evident packaging as defined by United 
States Pharmacopeia General Chapter 659, Packaging and Storage Requirements, 
including but not limited to unopened unit-dose and multiple-dose packaging. 
2) The following drugs shall not be donated to the program: 
a. Controlled substances; 
b. Drugs subject to a federal Food and Drug Administration managed risk evaluation and 
mitigation strategy pursuant to 21 U.S.C. Section 355-1 if inventory transfer is prohibited 
by such strategy; or 
c. Drugs that there is reason to believe are adulterated pursuant to Code Section 26-3-7. 
 
Rule 511-5-12-.04 Eligible recipients 
1) A pharmacy, hospital, wholesaler, reverse distributor, federally qualified health center, nonprofit 
clinic, healthcare facility, an entity participating in a drug donation or repository program 
pursuant to another state's law, or healthcare professional that is otherwise legally authorized to 
possess prescription drugs may become an eligible recipient for a period of one year by giving 
written notice to the Office of Pharmacy of the Department of Public Health. That notice shall 
serve as authority for the recipient to participate in the program for a period of one year, unless 
revoked by the Department. An eligible recipient may renew its authority by sending written 
notice in subsequent years. 
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2) The Department of Public Health shall publish on its website the list of authorized recipients. 
3) An entity which chooses to participate in the program shall comply with this Chapter, and shall 
make all records available for audit by this Department within five business days. Failure to 
comply with any provision of this Chapter or statutes governing prescription drugs may result in 
revocation of authority to participate in the program. Such revocation shall be provided as a 
written notice to the recipient and shall include the specific requirements that were violated and 
the corrective actions necessary for the recipient to reinstate its authority to participate in the 
program. 
 
Rule 511-5-12-.05 Receipt, storage, and handling of donated drugs by an eligible recipient 
1) A donor may donate drugs to an eligible recipient. 
2) An eligible recipient may receive, accept, donate, dispose, replenish, and store drugs that were 
either donated or repackaged as provided in paragraph (6) of this Rule. 
3) Prior to the first donation from a new donor, a recipient must verify and record the following: 
a. The donor meets the definition provided in DPH Rule 511-5-12-.01(2); 
b. The donor's name, address, phone number, and license number if applicable; 
c. The donor will only make donations of drugs in accordance with Code Section 31-8-301; 
d. The donor will insure integrity of any drug requiring temperature control other than 
"room temperature storage" that is delivered by enclosing in the drug's packaging a USP-
recognized method by which the eligible recipient can easily detect improper storage or 
temperature variations; and 
e. If applicable, the donor will remove or redact any patient names and prescription 
numbers on donated drugs or otherwise maintain patient confidentiality by executing a 
confidentiality agreement with the eligible recipient. 
4) An eligible recipient must store and maintain donated drugs in a secure and temperature 
controlled environment that meets the drug manufacturers' recommendations and United States 
Pharmacopeial Convention (USP) standards. 
5) A participating eligible recipient shall keep all donated drugs physically or electronically 
separated from other inventory. Donated inventory may be used to replenish purchased inventory 
with the same drug name and strength that was previously dispensed or administered to an 
eligible patient. Replenishment shall follow applicable federal 340B statute and Health Resources 
and Services Administration guidance. 
6) Drugs may be repackaged as necessary for storage, replenishment, dispensing, administration, or 
further donation. Repackaged drugs shall be labeled with the drug name, strength, and expiration 
date, and shall be kept in a separate designated area until inspected and initialed by a health care 
professional authorized to dispense. 
7) All donations received but not yet accepted into inventory shall be kept in a separate designated 
area. 
8) Prior to or upon accepting a donation into inventory, an eligible recipient shall maintain a written 
or electronic inventory of the donation, including: 
a. The transaction date; 
b. The name, strength, and quantity of each accepted drug; and 
c. The name, address and phone number of the donor. 
9) No record of a donation other than as described in paragraph (8) of this Rule shall be required. 
10) All records required by this Chapter shall be retained in physical or electronic format, on or off 
the recipient's premise for a period of six years. 
11) A donor or eligible recipient may contract with one another or a third-party to create and/or 
maintain records on each other's behalf. 
12) An identifier, such as a serial number or barcode, may be used in place of any or all information 
required by a record or label pursuant to this Chapter if it allows for such information to be 
readily retrievable. Upon audit by the Department of Public Health the identifier on requested 
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records shall be replaced with the original information. An identifier shall not be used on patient 
labels when dispensing or administering a drug. 
13) Pursuant to Code Section 26-4-115(b)(3)(A), a drug wholesaler, distributor, supplier, or 
outsourcing facility registered as provided in Chapter 13 of Title 16 or in Code Section 26-4-
115(a), except reverse distributors, shall comply with the requirements of 21 U.S.C. Sections 
360ee e-1 through 360eee-4 relating to drug supply chain security. If a donation's transaction 
history is required, the record of transaction history shall begin with the donor of the drugs, shall 
include all prior donations, and, if the drug was previously dispensed, shall not include drug 
information that is not required to be on the drug's label pursuant to Code Section 26-4-80(k)(1). 
 
Rule 511-5-12-.06 Dispensing and distribution of donated drugs 
1) An eligible recipient may only dispense or administer prescription drugs if otherwise permitted 
by law. 
2) Donation and the brokering or other facilitation of a donation of a drug pursuant to this program 
shall not be considered wholesale distribution and shall not require licensure as a wholesaler. 
3) Donated prescription drugs may only be dispensed to eligible patients pursuant to a valid 
prescription drug order in accordance with Title 26, Chapter 4. That patient shall be provided 
with appropriate counseling on the use of the prescription drug, including any potential side 
effects and the fact that the drug was donated. 
4) An eligible recipient may further donate unused prescription drugs to or receive unused 
prescription drugs from another eligible recipient in the program when one has the need for a 
drug and another has it available. An inventory of such donations shall be created in accordance 
with DPH Rule 511-5-12-.05(8) unless both eligible recipients are under common ownership or 
common control. 
5) An eligible recipient shall dispose of any drug that does not meet all of the requirements of Code 
Section 31-8-301 in one of the following ways: 
a. Return the drug to the donor; 
b. Destroy the drug through an incinerator licensed with the Environmental Protection 
Agency or other lawful method; or 
c. Transfer the drug to a reverse distributor. 
6) All such donated drugs to be disposed shall be quarantined in a separately designated area 
7) An eligible recipient shall maintain a written of electronic record of disposal, including: 
a. The disposal method as described in paragraph (5) of this Rule; 
b. The date of disposal or quarantine; and 
c. The name, strength, and quantity of each drug disposed. 
8) No record of disposal other than as described in paragraph (7) of this Rule shall be required. 
9) Donated drugs shall not be resold and shall be considered nonsaleable; provided, however, that 
reimbursement for any handling fee authorized pursuant to this Chapter shall not constitute 
reselling. 
10) Before dispensing a donated drug, an eligible recipient shall inspect the drug to determine that it 
has not adulterated. The drug must be repackaged into a new container or all previous patient 
information and pharmacy labeling must be redacted or removed from the donated container. 
11) Dispensed drugs must clearly indicate the final dispenser's information and current patient 
information, and shall be properly labeled in accordance with the regulations of the Georgia 
Board of Pharmacy. 
12) An eligible recipient that provides donated drugs to an eligible patient shall maintain patient-
specific written or electronic records in accordance with Georgia law and the regulations of the 
Board of Pharmacy. If also providing patients with purchased drugs, the eligible recipient shall 
also note, either on the face of a written prescription or in the electronic record of prescription, 
that a donated drug was dispensed to the patient. 
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13) An expiration date is required on all donated drugs dispensed. The expiration date shall be 
brought forward to the filled prescription. If multiple packaged donated drugs are used to fill a 
single prescription with varied expiration dates, the shortest expiration date shall be used for the 
dispensed prescription. 
14) Dispensed drugs shall not expire before the use by the patient based on the prescribing 
practitioner's directions for use or, for over-the-counter medicine not dispensed pursuant to a 
prescription, the directions for use on the package's label. 
15) Dispensed drugs subject to a United States Food and Drug Administration managed risk 
evaluation and mitigation strategy pursuant to 21 U.S.C. Section 355-1 shall be managed and 
dispensed according to the requirements of that strategy. 
 
Rule 511-5-12-.07 Handling fees 
1) An eligible recipient may not charge or collect any fees from an eligible patient for drugs 
dispensed pursuant to this program; provided, however that an eligible recipient may charge a 
handling fee for each donated drug that is dispensed. Such a handling fee shall not exceed the 
reasonable costs of participating in the program including but not limited to the current and 
anticipated costs of educating eligible donors, providing technical support to participating donors, 
shipping and handling, labor, storage, licensing, utilities, advertising, technology, supplies and 
equipment. 
2) Nothing in the preceding paragraph shall limit an eligible recipient from charging fees, including 
but not limited to a usual and customary charge, to donors, eligible recipients, health plans, 
pharmacy benefit managers, and other entities. 
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APPENDIX D: Iowa Prescription Drug Donation Repository Policy 
CHAPTER 109 
PRESCRIPTION DRUG DONATION REPOSITORY PROGRAM 
 
641—109.1(135M) Definitions. For purposes of this chapter, the following definitions apply: 
1) “Centralized repository” means a distributor approved by the contractor and licensed pursuant to 
657 IAC Chapter 17 that accepts donated drugs, conducts a safety inspection of the drugs, and 
ships the donated drugs to a local repository to be dispensed in compliance with this chapter and 
federal and state laws, rules and regulations. 
2) “Contractor” means the third party approved by the department to implement and administer the 
prescription drug donation repository program. 
3) “Controlled substance” means the same as defined in Iowa Code section 124.101. 
4) “Department” means the Iowa department of public health. 
5) “Indigent” means a person with an income that is below 200 percent of the federal poverty level 
(FPL) as defined by the most recently revised poverty income guidelines published by the United 
States Department of Health and Human Services. 
6) “Local repository” means a pharmacy or medical facility that elects to accept and dispense 
donated drugs and that meets the eligibility requirements of rule 641—109.3(135M). 
7) “Medical facility” means any of the following: 
a. A physician’s office. 
b. A hospital. 
c. A health clinic. 
d. A nonprofit health clinic, including a federally qualified health center as defined in 42 
U.S.C. § 1396d(l)(2)(B); a rural health clinic as defined in 42 U.S.C. § 1396d(l)(1); and a 
nonprofit health clinic that provides medical care to patients who are indigent, uninsured, 
or underinsured. 
e. A free clinic as defined in Iowa Code section 135.24. 
f. A charitable organization as defined in Iowa Code section 135.24. 
g. A nursing facility as defined in Iowa Code section 135C.1. 
8) “NDC #” means the unique national drug code number that identifies a specific approved drug. 
9) “Nurse practitioner” means an advanced registered nurse practitioner as defined in 655 IAC 
Chapter 7. 
10) “Pharmacist” means a pharmacist as defined in Iowa Code section 155A.3. 
11) “Pharmacy” means a pharmacy as defined in Iowa Code section 155A.3. 
12) “Physician” means an individual licensed under Iowa Code chapter 148, 150, or 150A. 
13) “Prescription drug” means the same as defined in Iowa Code section 155A.3 and includes cancer 
drugs and antirejection drugs, but does not include controlled substances. 
14) “Supplies” means the supplies necessary to administer the prescription drugs donated. 
15) “USP” means United States Pharmacopoeia. 
 
641—109.2(135M) Purpose. The overall purpose of this chapter is to establish administrative rules 
in accordance with Iowa Code chapter 135M relative to the following: 
1) Requirements for medical facilities and pharmacies to accept and dispense donated prescription 
drugs and supplies. 
2) Eligibility criteria for individuals to receive donated prescription drugs and supplies. 
 
641—109.3(135M) Eligibility criteria for program participation by medical facilities and 
pharmacies. 
109.3(1) To be eligible for participation in the prescription drug donation repository program, a 
medical facility or pharmacy shall be in compliance with all applicable federal and state laws, 
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including laws applicable to the storage and distribution of drugs and the appropriate licensure 
standards, and shall hold active, nonrestricted, state-issued licenses or registrations in good 
standing. 
109.3(2) Participation in the prescription drug donation repository program is voluntary. 
109.3(3) A pharmacy or medical facility may elect to participate in the prescription drug donation 
repository program by providing, on a form prescribed by the department and available on the 
program’s Web page, written notification to the centralized repository of all of the following: 
a. The name, street address, and telephone number of the pharmacy or medical facility, and 
any state-issued license or registration number issued to the pharmacy or medical facility, 
including the name of the issuing agency. 
b. The name and telephone number of the responsible pharmacist, physician or nurse 
practitioner who is employed by or under contract with the pharmacy or medical facility. 
c. A statement, signed and dated by the responsible pharmacist, physician or nurse 
practitioner, indicating that the pharmacy or medical facility meets the eligibility 
requirements under this rule and shall comply with the requirements of this chapter. 
109.3(4) Withdrawal from participation. A pharmacy or medical facility may withdraw from 
participation in the prescription drug donation repository program at any time by providing 
written notice to the centralized repository on a form prescribed by the department and available 
on the program’s Web page. 
 
641—109.4(135M) Standards and procedures for accepting donated prescription drugs and 
supplies. 
109.4(1) Any individual who is 18 years of age or older may donate legally obtained prescription 
drugs or supplies to the centralized repository or a local repository if the drugs or supplies meet 
the requirements of this rule, as determined by a pharmacist who is employed by or under 
contract with a drug repository. 
109.4(2) No drugs that require storage temperatures other than normal room temperature as 
specified by the manufacturer or United States Pharmacopoeia shall be donated or accepted as 
part of the prescription drug donation repository program. Drugs that require storage temperatures 
other than normal room temperature as specified by the manufacturer or USP shall not be donated 
or accepted because of the increased potential for these drugs to become adulterated. Excluded 
from this restriction are drugs donated directly from a drug manufacturer. 
109.4(3) Controlled substances shall not be donated or accepted. Pursuant to federal and state 
laws, a controlled substance cannot be returned or reused once the drug has been dispensed to a 
patient. 
109.4(4) The centralized repository or a local repository may accept a prescription drug only if all 
of the following requirements are met: 
a. The drug is in its original sealed and tamper-evident packaging. However, a drug in a 
single-unit dose or blister pack with the outside packaging opened may be accepted if the 
single-unit-dose packaging is undisturbed; 
b. The drug has been stored according to manufacturer or USP storage requirements; 
c. The packaging contains the lot number and expiration date of the drug. If the lot number 
is not retrievable, all specified medications will be destroyed in the event of a recall, 
pursuant to Iowa board of pharmacy rules; 
d. The drug has an expiration date that is more than six months after the date that the drug 
was donated. However, a donated prescription drug bearing an expiration date that is six 
months or less after the date the prescription drug was donated may be accepted and 
distributed if the drug is in high demand and can be dispensed for use prior to the drug's 
expiration date; 
e. The drug does not have any physical signs of tampering or adulteration, and there is no 
reason to believe that the drug is adulterated; 
54 
 
f. The packaging does not have any physical signs of tampering, misbranding, deterioration, 
compromised integrity or adulteration; and 
g. All drugs shall be inventoried at the centralized repository or a local repository. The 
inventory shall include the name of the drug, strength of the drug, quantity of the drug, 
and the date of donation if the drug has been continually under the control of a health 
care professional. If the drug has not been continually under the control of a health care 
professional, the repository shall collect a donation form provided by the prescription 
drug donation repository program that is signed by the person making the donation or that 
person’s authorized representative. 
109.4(5) A repository may accept supplies necessary to administer the prescription drugs donated 
only if all of the following requirements are met: 
a. The supplies are in their original, unopened, sealed packaging; 
b. The supplies are not adulterated or misbranded; and 
c. All supplies shall be inventoried at the centralized repository or a local repository. The 
inventory shall include a description of the supplies and the date donated. Such inventory 
shall be recorded on a form provided by the prescription drug donation repository 
program. 
109.4(6) Drugs and supplies may be donated on the premises of a participating centralized 
repository or a local repository to a person designated by the repository. A drop box may not be 
used to deliver or accept donations. 
 
641—109.5(135M) Standards and procedures for inspecting and storing donated prescription drugs 
and supplies. 
109.5(1) A licensed pharmacist employed by or under contract with the centralized repository or 
a local repository shall inspect donated prescription drugs and supplies to determine, to the extent 
reasonably possible in the judgment of the pharmacist, that the drugs and supplies are not 
adulterated or misbranded, are safe and suitable for dispensing, and are not ineligible drugs or 
supplies. The pharmacist who inspects the drugs shall sign an inspection record stating the above 
and attach it to the copy of the inventory or donor record provided with the drugs. If a local 
repository receives drugs and supplies from the centralized repository, the local repository does 
not need to reinspect the drugs and supplies. 
109.5(2) The centralized repository and local repositories shall store donated drugs and supplies 
in a secure storage area under environmental conditions appropriate for the drugs or supplies 
being stored. Donated drugs and supplies may not be stored with nondonated inventory. When 
donated drugs are not inspected immediately upon receipt, a repository shall quarantine the 
donated drugs separately from all dispensing stock until the donated drugs have been inspected 
and approved for dispensing under the program. 
109.5(3) Repositories shall destroy donated noncontrolled substances that are not suitable for 
dispensing and make a record of such destruction according to board of pharmacy rule 657—
8.8(124,155A). The destruction record shall be made in the same manner as prescribed for the 
record of return or destruction of a controlled substance in subrule 109.5(4). 
109.5(4) Controlled substances shall not be accepted for donation. 
a. Controlled substances submitted for donation shall be documented and returned 
immediately to the donor or the donor’s representative that provided the drugs. 
b. In the event controlled substances enter the centralized repository or a local repository 
and it is not possible or practicable to return the controlled substances to the donor or the 
donor’s representative due to inability to identify the donor or the donor’s representative 
or due to refusal by the donor or the donor’s representative to receive them, abandoned 
controlled substances shall be documented and destroyed beyond reclamation pursuant to 
rules of the board of pharmacy examiners. Such destruction shall be performed by a 
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pharmacist or other person that has authority to dispense controlled substances and shall 
be witnessed by another responsible adult employee of the repository. 
109.5(5) If a repository receives a recall notification, the repository shall perform a uniform 
destruction of all of the recalled prescription drugs in the repository and complete the destruction 
information form for all donated drugs destroyed. If a recalled drug has been dispensed, the 
repository shall immediately notify the recipient of the recalled drug pursuant to established drug 
recall procedures. 
 
641—109.6(135M) Standards and procedures for dispensing donated prescription drugs and 
supplies. 
109.6(1) Donated drugs and supplies may be dispensed only if the drugs or supplies are 
prescribed by a health care practitioner for use by an eligible individual and are dispensed by a 
licensed pharmacist, physician or nurse practitioner. 
109.6(2) A repository shall prioritize dispensing to an individual requesting drugs through the 
program as follows: 
a. First, to an indigent individual; 
b. Second, to an individual who has no active third-party prescription drug reimbursement 
coverage for the drug prescribed; and 
c. Third, to any other individual if an indigent or uninsured individual is unavailable. 
109.6(3) A repository shall dispense donated prescription drugs in compliance with applicable 
federal and state laws and regulations for dispensing prescription drugs, including all 
requirements relating to packaging, labeling, record keeping, drug utilization review, and patient 
counseling. 
109.6(4) The centralized repository and a local repository shall remove the original donor’s 
identification and the name of the dispensing pharmacy from the package prior to dispensing the 
drugs or supplies. 
109.6(5) The centralized repository and a local repository shall be responsible for drug recalls and 
shall have an established mechanism to notify recipients in the event of a drug recall. 
109.6(6) Prescription drugs or supplies donated under this program shall not be resold. 
109.6(7) The participating centralized repository and local repositories may distribute drugs and 
supplies donated under this program to other participating repositories for use pursuant to the 
program. The repository distributing the drugs or supplies shall complete a transfer form. 
 
641—109.7(135M) Eligibility criteria for individuals to receive donated prescription drugs and 
supplies. 
109.7(1) An individual who requests drugs from the prescription drug donation repository 
program shall certify to the repository that the individual is a resident of Iowa and meets one or 
both of the following criteria: 
a. Is indigent; 
b. Has no active third-party prescription drug reimbursement coverage for the drug 
prescribed. 
109.7(2) The local repository shall collect from each individual recipient a signed intake 
collection form provided by the department or its contractor. 
a. The intake collection form shall attest that: 
1. The individual is a resident of the state of Iowa; 
2. The individual’s income does not exceed 200 percent of the FPL; 
3. The individual is uninsured and has no prescription coverage or is underinsured 
and has no prescription coverage; 
4. The individual acknowledges that the drugs may have been donated; and 
5. The individual consents to a waiver of the requirement for child resistant 
packaging of the Poison Prevention Packaging Act. 
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b. The intake collection form will include an identification card to be given to the recipient 
for continued use for one year. 
109.7(3) The identification card is valid for one year or until the new federal poverty guidelines 
have been published for all prescriptions and supplies. 
109.7(4) A summary of data taken from the intake collection form is to be sent via regular mail, 
E-mail or facsimile to the centralized repository for data collection. 
 
641—109.8(135M) Forms and record keeping. 
109.8(1) The following forms developed for the administration of this program shall be utilized 
by participants of the program and are available on the program’s Web page on the department’s 
Web site, www.idph.state.ia.us. 
a. Prescription drug donation repository program notice of participation or withdrawal. 
b. Prescription drug donation repository program donation, transfer, inventory or 
destruction record. 
c. A record of medications dispensed. 
109.8(2) The prescription drug donation repository program recipient data collection form and 
identification card are given to the recipient by the local repository, and the completed data 
collection form is collected from the recipient by the local repository. 
109.8(3) Record-keeping requirements. 
a. All records required to be maintained as a part of the prescription drug donation 
repository program shall be maintained for a minimum of five years by participating 
pharmacies and medical facilities. 
b. Records required as part of this program shall be maintained pursuant to all current 
applicable practice acts. 
c. Data collected by the prescription drug donation repository program from all 
participating repositories shall be submitted quarterly or upon request to the centralized 
repository. The data will consist of the information collected in accordance with 641—
109.8(135M), Forms and record keeping. 
d. The centralized repository and the contractor shall submit reports to the department as 
required by the contract or upon request of the department. 
 
641—109.9(135M) Handling fee. A repository may charge the recipient of a donated drug a handling 
fee, not to exceed a maximum of 200 percent of the Medicaid professional dispensing fee as established 
by rule of the department of human services, to cover stocking and dispensing costs. A prescription drug 
dispensed through the prescription drug donation repository program shall not be eligible for 
reimbursement under the medical assistance program. 
 
641—109.10(135M) List of drugs and supplies program will accept. All prescription drugs, 
excluding controlled substances, that have been approved for medical use in the United States, that are 
listed in the USP or National Formulary (USP/NF), and that meet the criteria for donation established by 
these rules may be accepted for donation under the prescription drug donation repository program. 
 
641—109.11(135M) Exemption from disciplinary action, civil liability and criminal prosecution. 
109.11(1) A drug manufacturer acting reasonably and in good faith is not subject to criminal 
prosecution or civil liability for injury, death, or loss to a person or property for matters related to 
the donation, acceptance, or dispensing of a prescription drug manufactured by the drug 
manufacturer that is donated under this chapter, including liability for failure to transfer or 
communicate product or consumer information or the expiration date of the donated prescription 
drug. 
109.11(2) Except as provided in subrule 109.11(3), a person other than a drug manufacturer 
subject to subrule 109.11(1), acting reasonably and in good faith, is immune from civil liability 
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and criminal prosecution for injury to or the death of an individual to whom a donated 
prescription drug is dispensed under this chapter and shall be exempt from disciplinary action 
related to the person’s acts or omissions related to the donation, acceptance, distribution, or 
dispensing of a donated prescription drug under this chapter. 
109.11(3) The immunity and exemption provided in subrule 109.11(2) does not extend to any of 
the following: 
a. The donation, acceptance, distribution, or dispensing of a donated prescription drug under 
this chapter by a person if the person’s acts or omissions are not performed reasonably 
and in good faith. 
b. Acts or omissions outside the scope of the program. 
 
641—109.12 and 109.13 Reserved. 
 
641—109.14(135M) Prescription drug donation repository in disaster emergencies. The following 
are the requirements for the department to receive and distribute prescription drugs and supplies in 
preparation for a disaster emergency proclaimed by the governor or in preparation for a public health 
disaster. 
109.14(1) The department may receive prescription drugs and supplies directly from the 
prescription drug donation repository contractor and dispense prescription drugs and supplies 
through licensed personnel during or in preparation for a disaster emergency proclaimed by the 
governor pursuant to Iowa Code section 29C.6 or during or in preparation for a public health 
disaster as defined in 2009 Iowa Code Supplement section 135.140, subsection 6. 
109.14(2) The department may receive and distribute prescription drugs and supplies as defined 
in Iowa Code section 135.142 to any Iowan who has been a victim of a disaster emergency 
proclaimed by the governor. 
[ARC 8983B, IAB 8/11/10, effective 9/15/10] 
 
These rules are intended to implement Iowa Code chapter 135M 
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APPENDIX E: Wyoming Drug Donation Policy 
ARTICLE 16 - DRUG DONATION PROGRAM 
Wyoming Statutes as of September 2009 
 
35-7-1601. Short title. 
This act shall be known and may be cited as the "Drug Donation Program Act". 
 
35-7-1602. Definitions. 
a. For purposes of this act: 
1. "Prescription drug" means a pharmaceutical drug which is required by any applicable 
federal or state law to be dispensed only pursuant to a health care provider's prescription; 
and 
2. "Health care facility" means as defined in W.S. 35-2-901(a)(x) and that is additionally 
authorized to maintain an inventory of pharmaceutical drugs for dispensing to the 
facility's patients or residents. 
 
35-7-1603. Drug donation, redispensing and disposal program established; minimum requirements. 
a. The department shall establish pursuant to its rules and regulations a voluntary drug donation and 
disposal program as provided in this section. 
b. The drug donation and redispensing program shall have the following features: 
1. Any person or entity, including but not limited to a drug manufacturer, physician or 
health care facility, may donate drugs to the drug donation program; 
2. Drugs may be donated at a donation site maintained by the department, a take back event 
approved by the United States drug enforcement agency or at a physician's office, a 
pharmacy or a health care facility that elects to participate in the program and meets 
criteria established by the department; 
3. Drugs shall be redispensed under the drug donation program only if they are in their 
original, unopened, sealed packaging or, if the outside packaging is opened, the contents 
are single unit doses that are individually contained in unopened, tamper evident 
packaging; 
4. A drug shall not be redispensed within two (2) months of its expiration date or if the drug 
appears to be adulterated or misbranded in any way; 
5. Drugs in the donation program may be dispensed under the Medical Assistance and 
Services Act; 
6. Drugs shall be delivered either to the department's central collection facility, a take back 
event approved by the United States drug enforcement agency or one (1) of its regional 
collection facilities; 
7. Drugs available for redispensing shall be inventoried and posted on a list of drugs 
available for redispensing on the department's internet website. 
c. The drug drop off and disposal program shall have the following features: 
1. Drop off locations shall be located with donation sites as provided in paragraph (b)(ii) of 
this section or local law enforcement agencies approved by the United States drug 
enforcement agency to the extent necessary under federal law; 
2. Procedures shall be maintained for the documentation of all collected unused medication; 
3. Procedures shall be maintained for the environmentally safe disposal of unused 
medications; 
4. The department shall provide for public education of potential participating consumers 
about the availability of the drug disposal program and proper and effective disposal of 
unused medications; 
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5. The department shall cooperate with law enforcement agencies to the extent required for 
the collection under law enforcement supervision or the secure collection, storage, 
transport and destruction of controlled substances. 
 
35-7-1604. Program participants. 
a. A physician, pharmacy or health care facility that accepts donated drugs under the drug donation 
program shall comply with all applicable provisions of state and federal law relating to the 
storage, distribution and dispensing of such drugs and shall inspect all donated drugs prior to 
dispensing to determine if they appear to be adulterated or misbranded in any way. 
b. Donated drugs may be distributed to another participating physician, pharmacy or health care 
facility for dispensing. 
c. Donated drugs shall only be dispensed to a patient pursuant to prescription as required by law. 
d. A physician, pharmacy or health care facility may charge a handling fee for distributing or 
dispensing drugs under the drug donation program, as established by department rules and 
regulations, but shall not otherwise resell or charge for donated drugs. 
 
35-7-1605. Participant immunity. 
a. In the absence of bad faith, any person who participates in donating, accepting, distributing or 
dispensing drugs under this act shall be immune from civil or criminal liability or professional 
disciplinary action of any kind for any related injury, death or loss. No person, in the absence of 
bad faith, shall be liable for the bad faith of another relating to the provisions of this act. 
b. The immunity provided by this section shall not decrease or increase the civil or criminal liability 
of a drug manufacturer, distributor or dispenser that would have existed but for the donation. 
 
35-7-1606. Rules and regulations; agency cooperation. 
a. The department, in cooperation with the Wyoming board of pharmacy, shall promulgate rules and 
regulations implementing the drug donation program established by this act. Initial rules shall be 
promulgated within ninety (90) days after the effective date of this act and shall include: 
1. Eligibility criteria and other standards and procedures for participating physicians and 
health care facilities; 
2. Necessary forms for administration of the drug donation program, including forms for 
persons donating, accepting, distributing or dispensing drugs under the program; 
3. Maximum handling fees; 
4. Categories of drugs that the program will and will not accept. 
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